It’s no secret that heart disease — in its various forms — is the #1 killer in the United States.
In the US alone, someone dies from a heart attack every 60 seconds.It claims more lives than all forms of cancer combined.
Direct and indirect costs of heart disease total more than $320.1 billion—each and every year, with that number growing…
For over two decades, there have been two popular enemies in the fight against heart disease: cholesterol and high blood pressure.
But that’s all about to change, because…
The Current Drugs
Are Simply NOT
Saving Enough Lives!
Let’s begin with high blood pressure…
Among the estimated 68 million Americans who have elevated high blood pressure — about 70% of them use medication to attempt to control it.
Yet among those 47 million people, the American Society for Hypertension has reported that just 42.9% reduce their numbers to a level that’s healthy.
If you’re lucky enough to get your levels down with these drugs — you can probably expect many of the following life long side effects – including…
- Loss of essential minerals
- Kidney damage
- Lower libido
- Erectile dysfunction
- Digestive disorders
- Elevated triglycerides (blood fats) and ldl (bad) cholesterol
- Vision problems
- Anxiety and restlessness
- Sensitivity to sunlight
- Plus increased risk of developing cardiac arrhythmias and diabetes.
And it’s even worse if you’re over 60!
Lowering high blood pressure with medication can also prevent adequate blood flow to the heart — leading to cardiac arrhythmia and sudden cardiac death.
Think Cholesterol Drugs
Are Any Better? Think Again!
71 million US adults have high cholesterol — 2 in 3 don’t have it under control.
But it gets even scarier…
People with coronary heart disease or considered to be at high risk for coronary heart disease are typically prescribed statins, which are designed to lower cholesterol.
The problem is, according to a trial, statins are hardly a slam dunk. In many cases, as in the LIPS trial, those positively affected ranged from zero to 46% on the high end.
Other trials found that reduction in death from all causes due to these drugs ranged from zero to 29% on the upper end.
And this may be the worst part: half of the millions of statin prescriptions written each year are handed to female patients — and yet meta-analyses of numerous studies found these drugs show no overall mortality benefit for women!
In fact, the data has shown that statin drugs do NOT reduce the risk of death in 95% of the population, including healthy men with no pre-existing heart disease, women of any age, and the elderly.
And what about the small group who may actually benefit from statins?
Well, the risk is considerable — as they produce: muscle weakness, lethargy, liver dysfunction and cognitive disturbances ranging from confusion to transient amnesia.
With well over 30 million Americans now taking statin drugs…
The Risk to You
(and Those You Love)
Has Never Been Greater
Simply put, you or someone you care about may be putting your life on the line for drugs that offer little to no heart protection.
Not long ago, the US Food and Drug Administration (FDA) announced it would begin requiring additional warning labels for statin drugs. Among them are warnings that statins may increase your risk of:
- Liver damage
- Memory loss and confusion
- Type 2 diabetes
- Muscle weakness (for certain statins)
Statins have also been shown to increase your risk of diabetes via a number of different mechanisms.
New research also found that taking higher doses of the statins simvastatin (Zocor), atorvastatin (Lipitor) or rosuvastatin (Crestor) increases your risk of acute kidney injury by 34 percent, a condition that can be fatal.
Some experts are now urging that people on statins have an assessment of their kidney risks, similar to what used to be recommended regarding liver function.
Now, it may sound like I’m anti-drug across the board, but I’m absolutely not… I’m just in favor of drugs that actually work.
In fact, as you’ll see in a moment, I’m more than willing to put my own money on the line and back the drugs I feel will be effective and also represent significant investment potential.
Case in point:
A New Class of Drug that
Will Render Statins Obsolete
(And Make Early Investors a Fortune)
The U.S. Food and Drug Administration (FDA) has just approved the first new class of cholesterol-lowering drugs since statins flooded the market beginning in the 1980s.
Similar to the way statins work, by binding up cholesterol made in the liver so less of it circulates in the blood, this new class takes advantage of genetic mutations that regulate the level of LDL receptors in the liver.
This leads to more LDL receptors that can soak up LDL and, therefore, leave less cholesterol in the blood.
Like Stanley F. Fernandez, MD, PhD of New York’s University at Buffalo, who says…
“This class of drug may be a game-changer.”
And Eric D. Peterson, MD, MPH, FACC, the Executive Director of Duke Clinical Research Institute who went further to say…
“What’s important is that these drugs can not only lower cholesterol and LDL to very low levels, they generally look safe, and they seem to be trending toward improved outcomes. It’s quite exciting for the field.”
Even the New York Times calls it…
“…the first highly effective cholesterol-lowering medication in a generation.”
“These drugs are a big deal,” says Dr. Steven Nissen, chairman of cardiovascular medicine at Cleveland Clinic who is leading a study on this drug to see if it can not only lower cholesterol but actually reverse existing plaques in the arteries.
No Bad Cholesterol, No More Plaque…
Say Goodbye to Heart Disease Forever!
The latest guidelines from the American Heart Association and the American College of Cardiology did away with target cholesterol levels, and the new class of drugs helps patients get as safely close to zero cholesterol as possible.
“I think right now that will scare most people,” says Dr. Seth Martin, assistant professor of medicine and cardiology at Johns Hopkins School of Medicine. “But the science supports that it’s safe.”
With an efficacy level far higher than statins and initial side effects reported to be far lower—this new class of cholesterol drugs seems almost too good to be true.
But the initial studies are in — and given all the problems with statins (including a class action lawsuit against Lipitor, the most popular drug in history) — the FDA is thankfully being much more cautious this time around.
The approval of this new drug class means that we may finally have access to a real, life-saving treatment for the biggest killer in America.
The Hidden Blood Pressure Connection
One of the problems with high cholesterol is that it creates deposits of plaque along the walls of your arteries. This narrows your arteries, making it more difficult for blood to pass through them and carry oxygen to your heart and other organs.
When your blood doesn’t flow freely, your heart works harder to transport your blood, increasing your blood pressure.
So, if you lower your cholesterol, you create a freer path for blood to travel in your body. Lowering your blood pressure can also help reduce your cholesterol.
High blood pressure damages the walls of your arteries and forms scar tissues.
The scar tissue creates a trap for cholesterol.
Because of this link between cholesterol and blood pressure, taking steps to improve either your cholesterol or blood pressure usually improves both.
In fact, one study — published in the Journal of American College of Cardiology — found that “intensive cholesterol reduction lowers blood pressure and large artery stiffness.”
Which means this new class of drugs could help address not one but TWO of the biggest heart disease factors, and potentially replace the drugs used for both…
This Is Huge, But
Time Is of the Essence
If you or a loved one is at all concerned about heart disease, then this new drug could be a life-saver for you.
But time is of the essence, because as you’ve seen, statins and blood pressure medications are not only often ineffective — they’re often downright dangerous.
Who do you know that may be rolling the dice with these drugs right now?
Who in your life would benefit from a safer, more effective way to lower bad cholesterol and prevent a heart disaster from happening?
If someone in the U.S. dies every 60 seconds from a heart disease related incident — and experiences a heart attack every 34 seconds — how much time do you really have?
Can you afford to be patient and take the “wait and see” approach?
There’s Another Reason for My Urgency…
The fact that you’ve come this far with me means you’re probably concerned about not only your heart, but how you will live out the rest of your days.
That means you’re at least thinking about your retirement, and how you’re going to not only manage your health — but also pay for the retirement lifestyle you deserve.
Well, that may be the best news of all…
Because when it comes to this new class of drugs, one company stands above the rest.
I’m talking about a company with 3 DECADES of experience in this area — that looks to be the first to address what is easily a $10 billion dollar market in the U.S. alone…
Is this company healthy? Well, it survived Black Monday, Black Wednesday, The Asian Financial Crisis, The Dot-Com Bubble Burst and The Great Recession and every market hiccup in between.
The best part is, this stock is so much more than a stable investment… it has produced gains for investors time and time again.
Take the Great Recession… since then it has more than tripled.
Look at its growth on the following chart — it could hardly be more impressive:
And the best part? With this new drug class, there’s plenty of room to run!
This company is sitting on a superior product that solves a life-threatening problem faced by millions.
History Is About to Repeat Itself,
And Make Early Investors Rich (Again)
This has happened before:
In 1987, the pharmaceutical company Merck developed the first-ever statin, called Mevacor. It led to historic sales in its first year.
More importantly, the stock began selling at $3.84 and then hit $12.61 just a few years later — good for a 228% gain. But had you held onto it longer-term, you could have watched your profits hit 1,244% as the stock price soared to $51.62.
That’s enough to turn $5,000 into $67,214 and $10,000 into $134,427!
Even more impressively, had you been on board for both runs, and reinvested your original 228% gains — you could have turned $10,000 into $440,832!
Of course, Merck wasn’t the only company to ride this unprecedented wave:
In 1996, Pfizer stood at $8.04 per share. That same year, it released Lipitor, which went on to become the world’s first $10 billion dollar drug.
Just over 2 years later, Pfizer was trading at $29.72 — an astonishing 269% gain!
The Same Factors Which Led to
Potential Returns of $38,800… $134,427…
Even up to $440,832 Are All Present NOW
If you were to create the ultimate checklist for maximum profits with this type of investment, you’d find it all right here:
- It’s the first drug in an entirely new class: this sets the stage for massive sales growth that will almost inevitably drive the company’s stock price UP
- It addresses a widespread, life-threatening problem: with heart disease, inaction can be fatal. Customers are motivated, especially considering the “hit or miss” efficacy of current drugs. Lipitor was the best-selling drug in human history and this has the same addressable market.
- It’s backed by powerful research and medical authorities. New treatments are often met with skepticism. But in this case, the medical community is already showing strong early support for this drug based on clinical data, which will facilitate initial sales.
- It’s the BEST treatment available at the time. Going beyond statins and the limited impact of blood pressure medication, this treatment appears to be far more effective with far fewer side effects.
- The timing is perfect. Too early, and you risk investing before approval — which could be disastrous should anything go wrong with the FDA. Fortunately, we are still in the early stages of sales and growth — but not for long.
The bad news is that word is already getting out, and window to fully profit from this opportunity won’t last long. The good news is that there are more potential profits to capture because…
The Sheer Size of This
Opportunity Is Easily 10X Larger!
As if this opportunity couldn’t get any better… I was blown away when I began to analyze the other factors working in its favor.
For one, awareness of the problem is so much higher now. Back in the 1980’s and even 1990’s, many people were not yet aware of cholesterol and needed education, which of course slowed the sales process.
Today, not only does everyone know and already understand the importance of lowering cholesterol… they are also keenly aware of the side-effects and limitations with statins and drugs meant to address heart disease.
Plus, the heart disease epidemic has never been greater — it’s the number one killer in the United States and many other countries, responsible for one out of every three deaths.
And with health insurance being forced upon Americans via Obamacare, coupled with existing medical infrastructure and massive existing distribution channels — getting the product into people’s hands has never been easier.
2 More Reasons this Company
Will Spin Off Impressive Gains
Being first with a new class of drugs is not enough for this company, they are really going for the jugular and attempting to grab the biggest possible slice of the market.
Case in point: They recently acquired a European company, and as a result, obtained control of a drug that has been shown to increase good cholesterol by 161% while also reducing bad cholesterol by 45%.
This drug just passed stage 2 of its trial. And the company expects to start a phase 3 trial in the first half of 2016. That means we could see it in the market within just the next 2 years …and further their stranglehold on next generation cholesterol solutions.
But that’s not all… the company has another ace up its sleeve: biosimilars.
Biosimilars are nearly identical forms of drugs that have been proven to be as safe and effective as regular branded drugs.
They typically correspond to officially approved versions of original “innovator” products, and can be manufactured when the original product’s patent expires.
They’re also estimated to cost at least 20%–30% less than the drugs they’re modeled after.
With patents at risk — and 36% of the $140 billion in jeopardy of no longer having patent protection… biosimilars could become a BIG thing.
When you have a way of producing biosimilars more efficiently, which this company does, you are poised to seize a massive share of one of the biggest markets in the world.
Why the Clock Is Ticking
For You and Your Retirement
Now for the bad news — this company won’t have the monopoly on this class of drugs, it will only have the “jump” on others in this space… same with its ability to produce biosimilars more efficiently.
Others will surely catch up at some point… but our company has a head start.
Which means the window to ride all of the possible profits is narrow — hesitate and you could miss most or all of the gains as its stock soars.
Are you okay with missing out on potential six-figure gains on a stock that checks off virtually every box of the great blockbuster drugs of the past?
I sure hope not! All it takes is one big winner like this and your retirement begins to look a whole lot more comfortable.
That’s why I want to rush you all the information about this new class of drugs and how to invest in this company… while there’s still time.
I believe it’s the single greatest opportunity of our lifetime — to both protect our health AND our retirement dreams, with nearly guaranteed profits that come around only once every decade or so.
The report is called…
FORGET HEART DISEASE!
With One Stock That Can Help You
Enjoy a Long, Healthy, Prosperous Retirement
This detailed report will show you exactly how to invest in this breakthrough company. You’ll get everything you need to maximize your returns as this new class of drugs begins selling.
For instance, you’ll discover:
- How to leverage the fact that the stock has outperformed the S&P 500 every year since 2008 and by as much as 5-to-1…
- Why its new class of heart-saving meds and biosimilar technology are only the beginning! Learn about its pipeline of additional moneymakers and how that may affect your investment timing…
- What its massive international sales mean for its stock price…
- How the company uses its rapidly increasing free cash flow for growth and buybacks, and how you as an investor benefit…
- How to capitalize on the ever-growing dividend payouts to investors that have tripled since the program began in 2011…
- And much, much more!
This stock — and the new class of drugs it will help popularize — represent a historic opportunity. Not only will heart disease finally be able to be treated in a safe and effective way, but you can profit… just like investors did when statins were first introduced.
You’ll also get practical, step-by-step advice for locating this drug and how to discuss it with your medical practitioner, to see if it’s right for you (or any of your loved ones).
Because the truth is, you can only enjoy these profits and your retirement as long as you live — and I want to do my part to ensure you live the longest, healthiest life possible.
There’s so much more I could say about this report — and normally it would cost $197 and be a steal at that price.
But today you can get instant access to it FREE as a member of my service called…
… which could very well be the single best-performing biotech investing service available in its class.
My name is Bret Jensen, and I’m the biotech analyst here at Investors Alley.
I’ve been working and investing actively in the biotech industry for over 20 years, and my track record speaks for itself.
I’ve delivered winning performance for myself and readers — including a small army of double and triple-digit winners — year after year.
“Most importantly, I put my own money —
REAL MONEY — on the line with
every single recommendation I make.”
At a time where most newsletters use “model” portfolios (where no actual money is used and back-tested results to produce the so-called performance)…
… or where gurus typically never actually trade what they recommend…
… my members have the peace of mind to know that I’m personally invested each and every time I issue a recommendation. Period.
And keep in mind: due to the small, exclusive nature of our service, there’s absolutely no possible way for me to affect or control the price of any stock I recommend — so there’s never any conflict of interest.
I could tell you more about my accolades, like how:
- I have become one of Seeking Alpha’s top Healthcare and Biotech Investment experts
- I’ve been certified a top 50 financial blogger from the independent ranking service, TipRanks.
- And how an independent audit ranks me alongside the top 1% of investment analysts from investment houses like Piper Jaffray, Deutsche Bank and JP Morgan.
But that’s not really why you’re reading this, are you?
What matters is that I’ve proven my ability to find stocks like the one I’ve been telling you about today — in advance — and to help you fully capitalize on the profit opportunity.
- I led investors to 214% in Avanir Pharmaceuticals, who pioneered migraine medication, before their acquisition. Enough to turn $5,000 into $15,700!
- I gave the “buy” signal on Celgene, whose innovative cancer treatments helped investors make 267%… and grow $5,000 into $18,350!
- Eagle Pharmaceuticals was especially good to us — we netted 464% — which could have handed you back $28,200 on a mere $5,000 investment.
- We also saw huge returns of 646% with Zeltiq Aesthetics, a company who developed laser fat reduction technology… that’s over $37,300 on a $5k investment.
- And we bagged 834% on Novavax, a company who exploded thanks to its advances in vaccine technology. This made it possible to turn $5,000 into $46,700!
Impressive, right? Just those winners alone could have helped you…
Turn a $25,000 Portfolio into $146,250!
Are you seeing how this is every bit a six-figure opportunity?
Still, in all my years, I’ve never seen anything like the opportunity present with this company and this new class of cholesterol drugs.
This is truly a historic moment for anyone who is interested in both their health and profiting from the next great advancement in modern medicine.
So I’m doing everything I can to get this report into your hands.
I don’t want you to miss a single shred of the profit potential with this stock or any of the others I have in the pipeline.
Remember, every single recommendation I send you is one I’ve personally vetted with my own proprietary methodology that I feel confident enough to invest my own money in.
The “S-P-I-K-E” Secret
Behind My Proprietary Approach
While it’s impossible to capture the full breadth and depth of the approach I’ve perfected over many years of successful biotech investing — the acronym
S-P-I-K-E is a helpful way to remember 5 of the key factors.
Let’s look at them individually:
Stage – the first thing you must consider with any biotech investment is the STAGE it’s in. If a drug fails to make it through all three FDA trial phases, it doesn’t matter how “revolutionary” it is — it won’t ever see the light of day.
Naturally, drugs in an earlier stage of approval are higher risk because there’s less likelihood of making it all the way through.
Sometimes, you’ll see that a company has one promising drug at an earlier stage — whereas others drugs it is developing are in a later stage. This offsets risk.
Case in point: Horizon Pharma had multiple drugs and with several very close to final approval. We pulled the trigger, getting in at $2.40.
Today, it trades at over $18.00 — a 628% return!
Being able to turn $10,000 into $75,000 on a single trade isn’t bad, right?
And it’s only one factor. Next up is…
Price – This is really another way at looking for two factors: value and growth potential. Lower-priced stocks generally have greater relative value and more explosive growth potential.
And explosive growth potential is one of the biggest reasons to even invest in biotech at all, compared to slower-growing markets with less upside.
Generally, I invest in companies in the “pre-run-up” phase, however, there are times where there’s a significant opportunity outside of this phase — such as the stock we’ve been telling you about in this report.
Insiders – This isn’t always a factor, however, one very positive sign about a stock in this sector is clear signs of insider activity.
Normally, that might be worrisome, but when you see executives and those close to the firm buying up the stock in droves, it’s a very good sign they know something that may not be readily available to average investors.
My years of working inside this industry have not only given me connections to learn about such activity but led me to develop algorithms that can recognize signs of early activity and tip us off.
Key technology – Having unique tech provides an edge in any industry, but, in biotech, it’s that much more crucial to a company’s success.
Patents are part of it, but unique technology can boost profits in any number of areas — from manufacturing speed, cost-cutting, and beyond.
Companies usually highlight a technical advantage, but not always. We have exclusive methods we use to further dig into any possible strengths and factor these into the final recommendation accordingly.
Exchange – With the considerable expense of getting a new drug or technology out onto the market, it’s rare that an upstart company can do it all alone. Partnerships, based on the ability to ‘exchange’ value, are essential to success.
This is true whether a company needs to outsource some of its R&D to a larger player, or get help funding the latter stages of a clinical trial needed for final approval.
For example Agenus, a recent winner booking 153% returns for my readers had partnerships with Merck and GlaxoSmithKline.
These exchanges are typically win-win, a major “thumbs up” whenever you see them occur.
This last factor is weighed very heavily in our overall analysis algorithm that determines final trade recommendations.
And there you have it — just remember this SPIKE acronym as a summary of some key factors that go into the lucrative filtering and selection process within Biotech Gems.
The Only Portfolio Capable
of Safe Returns AND
Home Run Winners
Of course, the Biotech Gems methodology I just outlined helps us filter and select recommendations — but that doesn’t explain how it delivers the best of both worlds.
When you look at our current portfolio, and previous iterations, you’ll see a list of modest, single or double-digit winners that we consider “safe” plays.
These are usually stocks that have passed through more of the established criteria, are fundamentally sound and have a high probability of growth.
Of course, the upside isn’t as significant, but it’s important to have a good portion of the portfolio rooted in higher probability picks that ensure steady growth.
But that’s only HALF of the equation for us:
As you’ve seen throughout this report, there are dozens of opportunities to hit triple-digit profits — generating 5 or even 6-figures on a single trade, and certainly that much on multiple winning trades.
The ability to bank $75,000… $146,250… even up to $440,832… across these home runs, if you’re able to take action when we send out our recommendations.
Keep in mind: biotech is the ONLY sector that’s produced these kinds of gains over the last 15 years.
Even the almighty Apple and Google have had their ups and downs (with many investors in the red over that time), and investing in FANG tech companies or “startups” via crowdfunding carries a significant risk that most investors aren’t ready for.
So think about it like this…
Where else can you go for steady returns that beat the market by 2 or 3-to-1 AND still be able to hit home runs that add considerable cash to your retirement reserves?
Get More Lucrative Profit Opportunities—
Detailed in an Exclusive Report — Yours, FREE!
If you think the companies and returns we’ve discussed so far are exciting, you better hang onto your hat!
Because if you join us as a member of Biotech Gems today, I’m going to include a blockbuster report…
It is titled:
“1 Play, 3 Partnerships: The Stock with the Technology Big Pharma Wants”
And it’s all about a little-known company that has the potential to unlock $130 million in sales of a new drug.
It is currently collaborating with AbbVie, a company with a $113 billion market cap and partnering with Roche, a $48 billion international company.
By our estimates, this company could be looking at $100 million annually, and that’s just from two drugs.
Add to the fact that they’ve completed a Phase 3 trial for a Hepatitis B treatment and you begin to see even greater profit potential. Because Hepatitis B is the world’s most common liver virus, with 240 million people affected worldwide.
In fact, JP Morgan estimates this vaccine’s annual revenues could be $600 million in the U.S. alone.
And given that this is just one of many drugs in its pipeline—it’s easy to see how this represents triple-digit profit potential for those who get in soon enough.
Normally valued at $97, this report is yours FREE when you become a member of Biotech Gems today.
Biotech Gems Is the
Ultimate Biotech Investing Service
And ONLY One with Personal Attention
Before I go into everything you receive as a member, I have to emphasize two elements you absolutely won’t find in another service:
I “walk my talk” and invest real money, my own money, into every single stock I recommend. No hiding behind “model portfolios” where there’s no real risk or back-tested results that can be manipulated for better results… and…
I give you my personal email — not customer service, not some virtual assistant in the Philippines — my real email address… and I answer every single question members send me. I do that because this is about more than just money; I’m genuinely committed to the learning and ultimate success of my subscribers.
I feel compelled to mention these benefits first because they affect everything else you receive as part of the Biotech Gems service. You’ll also receive:
The complete Biotech Gems Portfolio — which features our proven, reliable “large cap” stock recommendations… coupled with the most explosive growth winners you’ve already seen to deliver gains like 1,496% on Horizon Pharma… 214% on Avanir… 464% on Eagle… 112% on Synageva… 700% on Novavax…153% on Agenus… and more.
The Biotech Gems Monthly Newsletter — which includes plain-English analysis of our recommendations, industry trends, and other in-depth insights that will help transform you into a world-class trader in this sector.
Instant Trade Alerts and Weekly Updates — so you never miss out on a key opportunity or shift in a key stock.
The moment we know about a new trade or adjustment in anything we’ve recommended, you will receive an email or notification so that you can take action immediately.
Every recommendation comes with clear buy and sell instructions, so you’re always perfectly clear on how to execute a trade.
You’ll also receive a weekly email summary of updates or changes — which members LOVE because it allows them to be thorough and never miss a thing.
Unlimited Questions and Help — FROM ME. Because as you learned a moment ago, you’ll have my own personal email address and are free to email me whenever you’re wondering about a stock, or need clarification on any detail with any of our recommendations.
And, you get 2 research reports — Forget Heart Disease… 1 Play, 3 Partnerships… worth $194—absolutely free!
What You Get Matters Less
Than What You DO With It
Of course, a great service means nothing if it doesn’t help you take action.
That’s why I’ve set it up to help you take full advantage of every opportunity I see — just like those who’ve been along with us have done.
Like one member who told us:
“I bought 1,000 shares of Eagle Pharmaceuticals at $16 and sold all at $39. I am very grateful for the $23,000 profit. In the future I hope we all will have more opportunities like Eagle. Besides your sage advice, I am grateful to you for bringing excitement into my life. I feel like Hugh Hefner on steroids.”
Or another Biotech Gems investor, who said:
“Just wanted to thank you for some of these small cap biotech gems. I just sold 3 with returns of 61%, 68% and 78%!! All in a matter of months. Anyway, Thanks again! Your advice is well worth the price of admission!!”
And an overjoyed member who exclaimed:
“Don’t have the words to thank you enough for this stock pick! Up 66% in one day! I had to sell it, as I need the money for something that just came up, but your stock pick was a life changer for me. Thank you!!”
At Just $1.10 Per Day, You’ll
Never Find a Better Value
Because you’re a new subscriber, and because of this historic opportunity that could truly save lives — I’m offering Biotech Gems at the lowest rate available.
While we do offer some lower priced services, none deliver both the safety and home run potential that you’ll find with Biotech Gems.
Anytime you can make consistent, low-risk returns and then also take $5,000 and turn it into potential gains of $75,000… $146,250 or much more — well, that’s pretty amazing!
But then again, because I’m personally trading every stock I recommend — and giving out my personal email — I’m not looking for the largest possible membership.
I’m more focused on helping a select group of individuals who recognize this opportunity to live a safe, happy, healthy retirement — without compromise.
Normally, this service is $999 for the year and a steal at that price.
But we’re letting a small number of investors try out a quarter of the service, and experience its profit-generating potential, for just four quarterly installments of only $99.
That’s roughly $1.10 per day for recommendations and training that can help you generate 100X or even 1,000X what you’re paying to join us!
I’ll Take ALL the Risk
for a FULL ONE YEAR Period…
This way, you’ll have two powerful assurances from us:
FIRST, you get our 60-day satisfaction guarantee — which states you must be overjoyed with the service on every level. In the unlikely event you’re not thrilled, for any reason or for no reason at all, just let me know and receive a full, no-questions-asked refund. That’s our 100% money back guarantee.
SECOND, I stand by the performance of Biotech Gems. That means you get one full year to prove to yourself that this is the REAL deal. If any time after that you decide the portfolio isn’t performing as you expected just call or email (you’ll have my personal email address!) to ask for your money back. I will fully refund the entire most recent quarterly payment. That’s my promise.
And remember, that is not only enough time to test this out… it’s enough time to potentially multiply your money many, many times over.
Here’s how it works:
Over the course of the next year, we’ll document every single one of our trades — just as we have been.
Then, at the end of the 12-month period, the Biotech Gems service must have generated a positive overall return across published trades — otherwise, you’re entitled to a full refund of your most recent quarterly installment. No hard feelings, no questions asked. Just a prompt, courteous, full refund.
In Your Heart You Know
This is the Right Decision
Throughout this report, you’ve learned about the life-changing potential of this new class of heart medication — and the historic profit opportunity it represents.
And now, you just learned that you can see EVERYTHING — including the reports and entire service… put it into action… and experience its performance on your own… with zero risk on your part for 60 days.
Then, if you remain on board with us an annual member, you’ll be protected all the way up to the FULL 12-month period.
So, here’s what I recommend you do…
First, simply click here or on the button below and get started with your membership.
Assuming enrollment is still open, you’ll be able to complete your registration and pay for membership.
Because you ARE among the first in our community to receive this invitation… if you act now, there’s a good chance you’ll be able to secure a spot in this program.
And again, you’ll immediately receive over $194 in bonus reports —
including FORGET HEART DISEASE — which could help
save the life of someone you know and love.
This may be the best opportunity you EVER have to protect both your health and wealth while creating the long and prosperous retirement you deserve.
I greatly look forward to speaking with you each week, by email, via our alerts and newsletter — helping you profit from the many stocks set to explode in the months ahead.
Once you discover just how EASY this really is… you may never want to touch traditional stocks or trading, ever again.
Here’s to lifelong profits…
I’ll look forward to seeing your first email in my inbox.
Chief Investment Advisor
P.S. — Upon activating your membership, you’ll get immediate access to the 2 FREE reports worth $194, including FORGET HEART DISEASE and 4 other reports that show you multiple stocks offering some of the best opportunities in the market right now.
Each report represents a triple-digit profit opportunity, similar to how we banked over 700% on Novavax or 1,496% onHorizon Pharma.
Those two trades alone would have been enough to turn a mere $10,000 into well over SIX-FIGURES — even if you mistakenly got out before their peak price and profit.
P.P.S. — The exact details behind all of the strategies I’ve shared inside this report—including the exact heart-saving stock that’s ready to explode… how to invest in it… when to get in and out…along with the emerging stocks that have triple-digit profit potential… will all be revealed to you the moment you activate your risk-free membership.
Remember, you must be blown away, or you can cancel any time in the first 60 days… and not only that, but the overall service MUST be profitable across its published recommendations, or it’s FREE.
See details above and why you have nothing to lose and only massive potential returns to gain.
[ExitPopup exitpopupurl=”http%3A//www.investorsalley.com/amember/signup/cFCBS0sY” exitpopupcookiexpdays=”0″ exitpopsplash=”%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%20W%20A%20I%20T%20%21%21%21%20%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%7E%5Cn%5CnDon%5C%27t%20let%20this%20opportunity%20pass%20you%20by%20while%20other%5Cninvestors%20are%20making%20extreme%20profits%20from%20one%20of%20%5Cnthe%20hottest%20sectors%20over%20the%20past%2015%20years.%5Cn%5CnBiotech%20Gems%20gives%20you%20winner%20after%20winner%20for%20a%5Cnfraction%20of%20the%20price%20many%20of%20those%20other%20research%5Cnfirms%20charge.%20%5Cn%5CnClick%20%5C%22Stay%20on%20Page%5C%22%20to%20take%20just%20one%20minute%20to%20%5Cnfind%20out%20more.” ] [/ExitPopup]